Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 473 - Heterocyclic compounds containing purine ring systems
Patents for C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
01/2008
01/08/2008US7317025 Non-peptidic NPY Y2 receptor inhibitors
01/08/2008US7317017 A2B adenosine receptor antagonists
01/03/2008WO2008000744A2 2-0'-methyladen0sine derivatives and their use as agonists or antagonists of an adenosine receptor
01/03/2008WO2008000692A2 Pyrimidine and quinazoline derivatives as modulators of somatostatine receptor activity
01/03/2008WO2007125331A3 Amino-ethyl-amino-aryl (aeaa) compounds and their use
01/03/2008WO2007107696A3 Pharmaceutically acceptable salts and polymorphic forms
01/03/2008US20080004293 Adenosine receptor antagonists and methods of making and using the same
01/03/2008US20080004292 Substituted 8-[6-amino-3-pyridyl]xanthines
01/03/2008CA2655397A1 Pyrimidine and quinazoline derivatives
01/03/2008CA2654371A1 Therapeutic compounds
01/02/2008EP1873156A1 Process for the preparation of 6-[[(alkoxy)carbonyl]amino]-9H-Purine-9-acetic acid and 4-[(alkoxycarbonyl)amino]-2-oxo-1(2H)-Pyrimidineacetic acid derivatives as synthons for the synthesis of peptide nucleic acids
01/02/2008CN101096370A Valine entecavir and preparation method and application
12/2007
12/27/2007WO2007148185A2 Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
12/27/2007WO2007147659A1 Adenosine a3 receptor agonists
12/27/2007WO2007125321A3 Purine and deazapurine derivatives as pharmaceutical compounds
12/27/2007WO2007125315A3 Pharmaceutical compounds
12/27/2007US20070299258 Therapeutic compounds and their use in cancer
12/27/2007US20070299090 Substituted 8-aminoalkoxy-xanthine compounds and compositions useful in the treatment of hyperlipidemia and diabetes
12/27/2007CA2655598A1 Substituted 8-[6-amino-3-pyridyl]xanthines
12/27/2007CA2649648A1 Adenosine a3 receptor agonists
12/26/2007EP1870411A1 Process for the preparation and purification of valgancyclovir
12/26/2007EP1869047A1 Purine derivatives as receptor-tyrosine kinase activityinhibitors
12/26/2007EP0837630B1 Prodrugs of pharmaceuticals with improved bioavailability
12/26/2007CN101092400A 黄嘌呤氧化酶抑制剂 Xanthine oxidase inhibitors
12/25/2007US7312326 Fluorescent labeled nucleotide derivatives
12/25/2007US7312223 8-Amino-7-phenylmethyl-1-ethyl-3,7-dihydro-3-(2-hydroxyethyl)-purine-2,6-dione derivatives; urogenital, respiratory system, kidney, cardiovascular, autoimmune or brain disorders; angina pectoris, hypertension, restenosis; anticarcinogenic, hypoglycemic, antiischemic, and hypotensive agents; diabetes
12/20/2007US20070293517 Derivatives Of Chemotherapeutic Agents With A Formaldehyde Releasing Moiety
12/19/2007EP1866310A1 2,3-substituted fused pyrimidin-4(3h)-ones as vr1 antagonists
12/19/2007CN101090899A 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors
12/19/2007CN101089010A 2'-fluoroncucleosides
12/18/2007US7309615 High quantum yield acridinium compounds and their uses in improving assay sensitivity
12/13/2007WO2007142576A1 2-thioxanthine derivatives acting as mpo-inhibitors
12/13/2007CA2653774A1 2-thioxanthine derivatives acting as mpo-inhibitors
12/12/2007EP1863815A1 Substituted 9-alkyladenines and the use thereof
12/12/2007CN101087790A Xanthine derivatives with hm74a receptor activity
12/11/2007US7307167 Production method of 2,6-dihalopurine
12/11/2007US7307166 8-Substituted purines; ring-cleaved aldose (guanosine 2',3' dialcohol); inflammatory diseases and bacterial infections; modifying hematopoiesis in animals with damage caused by irradiation, chemotherapy, poisoning; improve host leukocyte-mediated defenses against infection.
12/11/2007US7307065 Therapy for hepatitis B virus infection ; antiproliferative agents; antitumor agents; anticancer agents
12/06/2007WO2007121917A3 Purine derivatives as adenosine receptor activator
12/06/2007WO2007110649A3 Process for the preparation of 2,6,9-trisubstituted purines
12/06/2007US20070282105 e.g. 3-[2-(4-aminophenyl)ethyl]-8-benzyl-7-(2-ethylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility
12/06/2007US20070282104 Method for producing nucleoside derivatives
12/06/2007US20070282100 Boronic ester and acid compounds, synthesis and uses
12/06/2007US20070281952 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists
12/05/2007EP1861412A1 Adenosine derivatives having a2a receptor activity
12/05/2007EP1208085B1 Benzanilides as potassium channel openers
12/05/2007EP1169294B1 Pharmaceutical compounds
12/04/2007US7304077 Asthma, rhinitis therapy
12/04/2007US7304070 eg 8-(4-{[3-(2-methylphenyl)(1,2,4-oxadiazol-5-yl)]methoxy}phenyl)-1,3-dipropyl-1,3,7-trihydropurine-2,6-dione; atherosclerosis, angiogenesis, diabetic retinopathy, cancer, asthma, diarrhea, senile dementia, Alzheimer's disease, or Parkinson's disease
12/04/2007US7303773 Process for enriching extracts of natural theanine
12/04/2007CA2345622C Tricyclic .delta.3-piperidines as .alpha.2-antagonists
12/04/2007CA2212205C Use of xanthine derivatives for the modulation of apoptosis
11/2007
11/29/2007WO2007137214A1 Methods for preventing or treating acute and chronic pain
11/29/2007WO2007136668A2 N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
11/29/2007US20070275912 Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase
11/29/2007US20070274910 e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility
11/29/2007CA2669813A1 Substituted aryl piperidinylalkynyladenosines as a2ar agonists
11/29/2007CA2652038A1 Methods for preventing or treating acute and chronic pain
11/29/2007CA2649913A1 N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
11/28/2007EP0983222B1 Pharmaceutical agents for the treatment of cerebral amyloidosis
11/28/2007CN100351243C Peptide nucleic acid oligomers from 1-benzenesulfonyl-3-amino acid side chain-4-(2-nucleobase(acetyl))-piperazin-2-ones
11/28/2007CN100351242C Processes and intermediates for preparing anti-cancer compounds
11/27/2007US7300945 For therapy of of certain central nervous system (CNS) diseases, anxiety, depression, a sleep disorder, schizophrenia, or attention deficit-hyperactivity disorder
11/27/2007US7300923 Partial and full agonists of A1 adenosine receptors
11/22/2007WO2007133615A2 Hand-held aspiration syringe and methods
11/22/2007US20070270444 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3
11/22/2007US20070270442 Combination of a Cdk Inhibitor and Cs-682 or a Metabolite Thereof
11/22/2007US20070270412 Novel pharmaceuticals
11/22/2007CA2652263A1 Therapeutic compounds and their use in cancer
11/21/2007EP1857458A1 Process for the preparation of abacavir
11/21/2007CN101074231A [18F] fluoraro-marked purine compound, its production and use
11/21/2007CN101074230A Production of 2-amino-6-fluorine-9-(4-hydroxy-3-methylol-butyl) purine and its intermediate
11/21/2007CN100349913C 2'-fluoronucleosides
11/15/2007WO2007130783A2 Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
11/15/2007WO2007128752A1 Pyridyl compounds
11/15/2007WO2007128721A1 Polymorphs
11/15/2007US20070265445 (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide; stable under relative humidity stress
11/15/2007US20070265284 Substituted 8-aminoalkylthioxanthines, and their use as inhibitors of dipeptidyl peptidase iv
11/15/2007US20070265283 Xanthine Oxidase Inhibitor
11/15/2007CA2810839A1 Polymorphs
11/15/2007CA2810522A1 Polymorphs
11/15/2007CA2810295A1 Polymorphs
11/15/2007CA2651089A1 Polymorphs
11/14/2007EP1853602A1 Chemical compounds
11/14/2007EP1490369B1 Production method of 2,6-dihalopurine
11/14/2007CN101072787A Substituted adenines and the use thereof
11/14/2007CN101072777A Drying process for preparing crystalline solid famciclovir
11/14/2007CN101072567A Ready-for-use injectable solution of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amine-1h-purin-6(9h)-one
11/08/2007WO2007125321A2 Purine and deazapurine derivatives as pharmaceutical compounds
11/08/2007WO2007125315A2 Pharmaceutical compounds
11/08/2007WO2007103970A3 Compositions and methods for treating respiratory disorders
11/08/2007US20070259823 Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
11/08/2007CA2649995A1 Amino-ethyl-amino-aryl (aeaa) compounds and their use
11/07/2007EP1852435A1 A process for the manufacture of famciclovir using phase-transfer catalysts
11/07/2007CN101068814A An isolated valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
11/07/2007CN101068776A Arylsulfonylnaphthalene derivatives as 5ht2a antagonists
11/07/2007CN101068772A N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
11/07/2007CN100347161C Pna单体和前体 Pna monomers and precursors
11/07/2007CN100346786C Substituted benzimidazole compounds and their use for the treatment of cancer
11/06/2007US7291623 Compounds that interact with kinases
1 ... 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 ... 120